Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06706427 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Status, Referencesv3
  2. Primary completion date: Mar 26, 2025 to Nov 30, 2025
    • Primary endpoints revised (2)
    • Eligibility criteria revised
    • Secondary endpoints revised (4)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this study is to evaluate the safety, tolerability, and efficacy of subretinal injection of NGGT001 in patients with Bietti Crystalline Corneoretinal Dystrophy (BCD) and to recommend the optimal dosage for future clinical administration.
Trial Details
NCT Number NCT06706427
Lead Sponsor NGGT (Suzhou) Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Bietti Crystalline Corneoretinal Dystrophy
Related terms Bietti Crystalline Dystrophy
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov